Minocycline Hydrochloride

N.º de catálogoS4226 Lote:S422604

Datos técnicos

Fórmula	C₂₃H₂₇N₃O₇.HCl
Peso molecular	493.94	Número CAS	13614-98-7
Solubilidad (25°C)*	In vitro	Water	6 mg/mL (12.14 mM)
		DMSO	Insoluble
		Ethanol	Insoluble
* <1 mg/ml significa ligeramente soluble o insoluble. * Tenga en cuenta que Selleck prueba la solubilidad de todos los compuestos internamente, y la solubilidad real puede diferir ligeramente de los valores publicados. Esto es normal y se debe a ligeras variaciones entre lotes. * Envío a temperatura ambiente (Las pruebas de estabilidad demuestran que este producto se puede enviar sin medidas de refrigeración.)

Preparación de soluciones madre

Actividad biológica

Descripción	Minocycline HCl es el antibiótico de tetraciclina más liposoluble y más activo, se une a la subunidad ribosomal 30S, impidiendo la unión del ARNt al complejo ARNm-ribosoma e interfiriendo con la síntesis de proteínas.
In vitro	Minocycline is a second-generation tetracycline used in humans, which effectively crosses the blood−brain barrier. It inhibits the activity of caspase-1, caspase-3, inducible form of nitric oxide synthetase (iNOS) and p38 mitogen-activated protein kinase (MAPK). After experimental ischemia, minocycline inhibits caspase-1 and inducible nitric oxide synthetase (iNOS) upregulation, and decreases infarct size. Minocycline inhibits mitochondrial permeability-transition-mediated cytochrome c release. Minocycline-mediated inhibition of cytochrome c release is demonstrated in vivo, in cells, and in isolated mitochondria.
In vivo	Minocycline is a semi-synthetic tetracycline derivative which is well absorbed and distributed in body tissues and is suitable for twice daily administration. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). Minocycline is remarkable neuroprotective qualities in models of cerebral ischaemia, traumatic brain injury, and Huntington's and Parkinson's disease. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.

Descripción

Minocycline HCl es el antibiótico de tetraciclina más liposoluble y más activo, se une a la subunidad ribosomal 30S, impidiendo la unión del ARNt al complejo ARNm-ribosoma e interfiriendo con la síntesis de proteínas.

In vitro

Minocycline is a second-generation tetracycline used in humans, which effectively crosses the blood−brain barrier. It inhibits the activity of caspase-1, caspase-3, inducible form of nitric oxide synthetase (iNOS) and p38 mitogen-activated protein kinase (MAPK). After experimental ischemia, minocycline inhibits caspase-1 and inducible nitric oxide synthetase (iNOS) upregulation, and decreases infarct size. Minocycline inhibits mitochondrial permeability-transition-mediated cytochrome c release. Minocycline-mediated inhibition of cytochrome c release is demonstrated in vivo, in cells, and in isolated mitochondria.

In vivo

Minocycline is a semi-synthetic tetracycline derivative which is well absorbed and distributed in body tissues and is suitable for twice daily administration. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo).

Minocycline is remarkable neuroprotective qualities in models of cerebral ischaemia, traumatic brain injury, and Huntington's and Parkinson's disease. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.

Protocolo (de referencia)

Ensayo celular:^{^[4]}	Líneas celulares OVCAR-3, SKOV-3 and A2780 cells Concentraciones IC50 values of 62.0, 56.1 and 59.5 μM, respectively Tiempo de incubación 72 h Método Cells were treated with various concentrations of drug for 72 h.

Referencias

https://pubmed.ncbi.nlm.nih.gov/1173232/
https://pubmed.ncbi.nlm.nih.gov/11986668/
https://pubmed.ncbi.nlm.nih.gov/12930891/

https://pubmed.ncbi.nlm.nih.gov/22252097/

Expandir

Selleck's Minocycline Hydrochloride Ha sido citado por 45 Publicaciones

Epitranscriptomic regulation of mRNA stability in pivotal transcription factors modulates the second cell fate decision [ Nat Commun, 2026, 17(1):5800]	PubMed: 42045194
CRISPR-based screening identifies the role of KRAB-containing transcription factors ZIM3 and ZNF394 in human major zygotic genome activation [ Cell Rep, 2025, 44(8):116015]	PubMed: 40674211
Single-cell dynamic RNA and glycosylation sequencing reveals the mechanism underlying the differentiation of pluripotent stem cells into hematopoietic stem cells [ Hum Cell, 2025, 38(4):110]	PubMed: 40425941
Lipidomics reveals dysregulated lipid profiles in lipopolysaccharide administration-induced cognitive impairments [ Brain Res Bull, 2025, 234:111655]	PubMed: 41297799
Flash optimization of drug combinations for Acinetobacter baumannii with IDentif.AI-AMR [ NPJ Antimicrob Resist, 2025, 3(1):12]	PubMed: 39984645
Minocycline prevents photoreceptor degeneration in Retinitis pigmentosa through modulating mitochondrial homeostasis [ International Immunopharmacology, 2024 Sep 30, 112703]	PubMed: 39018687
Calcitonin gene-related peptide attenuated discogenic low back pain in rats possibly via inhibiting microglia activation [ Heliyon, 2024, 10(3):e25906]	PubMed: 38371980
Bilineage embryo-like structure from EPS cells can produce live mice with tetraploid trophectoderm [ Protein Cell, 2023, 14(4):262-278]	PubMed: 37084236
Comparative assessment of embryotoxicity of 2,4,6-triiodophenol to mouse blastoid and pre-implantation embryo models [ Ecotoxicol Environ Saf, 2023, 252:114608]	PubMed: 36738612
Adolescent microglia stimulation produces long-lasting protection against chronic stress-induced behavioral abnormalities in adult male mice [ Brain Behav Immun, 2022, 105:44-66]	PubMed: 35781008

POLÍTICA DE DEVOLUCIÓN
La Política de Devolución Incondicional de Selleck Chemical garantiza una experiencia de compra en línea fluida para nuestros clientes. Si no está satisfecho con su compra de alguna manera, puede devolver cualquier artículo(s) dentro de los 7 días posteriores a su recepción. En caso de problemas de calidad del producto, ya sean problemas relacionados con el protocolo o con el producto, puede devolver cualquier artículo(s) dentro de los 365 días a partir de la fecha de compra original. Siga las instrucciones a continuación al devolver productos.

ENVÍO Y ALMACENAMIENTO
Los productos Selleck se transportan a temperatura ambiente. Si recibe el producto a temperatura ambiente, tenga la seguridad de que el Departamento de Inspección de Calidad de Selleck ha realizado experimentos para verificar que la colocación a temperatura normal durante un mes no afectará la actividad biológica de los productos en polvo. Después de la recogida, guarde el producto de acuerdo con los requisitos descritos en la hoja de datos. La mayoría de los productos Selleck son estables en las condiciones recomendadas.

NO PARA USO HUMANO, DIAGNÓSTICO VETERINARIO O TERAPÉUTICO.